Log in to save to my catalogue

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-con...

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-con...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751228488

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy and in combination with sorafenib. We aimed to assess efficacy and safety of tivantinib for second-line treatment of advanced hepatocellular carcinoma. Methods In this completed, multicentre,...

Alternative Titles

Full title

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1751228488

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751228488

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(12)70490-4

How to access this item